Japan-based Astellas Pharma Inc. (TYO: 4503) is set to establish a joint venture (JV) with compatriot firm YASKAWA Electric Corporation (TYO: 6506). The collaboration aims to develop a cell therapy product manufacturing platform utilizing Maholo, a cutting-edge dual-arm robot developed by YASKAWA’s subsidiary, the Robotic Biology Institute. This innovative platform will enhance precision and reproducibility in cell therapy manufacturing.
JV Details and Investment
The joint venture will have a registered capital of JPY 4.5 billion (USD 30.5 million), with Astellas holding a 60% stake. The JV will focus on developing a highly precise and reproducible manufacturing process using Maholo, optimizing the digitized manufacturing process with AI.
Technological Innovation and GMP Compliance
A key goal of the JV is to develop a cell manufacturing platform that meets Good Manufacturing Practice (GMP) conditions. This platform will be capable of manufacturing cell therapy product candidates for partners, including academia and startups, as well as producing investigational drugs in GMP facilities.
Collaboration and Open Innovation
The JV will also offer platform access to startups and academic institutions, fostering a collaborative environment for innovation in the cell therapy field. By leveraging Maholo’s advanced technology, the JV aims to set new standards in cell therapy manufacturing and accelerate the development of novel treatments.-Fineline Info & Tech
Leave a Reply